Hepa-Merz (Ornithine Aspartate)

Hepa‑Merz is indicated for clinical situations where reduction of blood ammonia and support of hepatic function are desired.

• Management of hepatic encephalopathy associated with liver disease.
• Adjunctive therapy in patients with compensated or decompensated liver cirrhosis.
• Support during acute episodes of hyperammonemia.
• Use as part of a nutritional strategy to improve nitrogen balance in chronic liver conditions.
• May be considered in pre‑operative preparation for patients with impaired liver function.
• Potential role in reducing portal hypertension complications when combined with standard care.
• Assistance in stabilizing metabolic parameters during liver transplantation evaluation.

The safety profile of Hepa‑Merz reflects the pharmacology of ornithine aspartate, with most patients experiencing mild, transient reactions.

Common

• Mild nausea or gastrointestinal discomfort.
• Transient headache or dizziness.
• Injection site erythema or mild pain.
• Temporary increase in serum ammonia levels that resolves spontaneously.

Serious

• Severe hypersensitivity reactions, including rash, pruritus, or anaphylaxis.
• Hepatic decompensation manifested by jaundice, ascites, or encephalopathy worsening.
• Electrolyte disturbances such as hypernatremia in rare cases.

When prescribing Hepa‑Merz, clinicians should evaluate patient history and monitor clinical parameters to minimize risks.

• Assess baseline liver function tests before initiating therapy.
• Use caution in patients with renal impairment due to altered amino‑acid handling.
• Monitor serum ammonia and electrolytes regularly during treatment.
• Avoid use in individuals with known hypersensitivity to ornithine or aspartate.
• Consider dose adjustment or discontinuation if signs of worsening hepatic encephalopathy appear.
• Evaluate pregnancy and lactation status; safety data are limited.
• Review concomitant medications that affect nitrogen metabolism.

Ornithine aspartate can interact with other agents that influence ammonia metabolism or renal excretion.

Avoid

• Concurrent use with high‑dose lactulose or rifaximin without medical supervision, as additive effects on ammonia may occur.
• Combination with nephrotoxic drugs in patients with compromised renal function.

Use with caution

• Co‑administration with diuretics, especially spironolactone, may affect electrolyte balance.
• Concurrent use of other amino‑acid supplements could alter plasma concentrations.
• Interaction with antiepileptic drugs that are metabolized via hepatic pathways should be monitored.